Ischemic Stroke Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents

Ischemic stroke develops due to an obstruction within a blood vessel which supply blood to the brain. The underlying condition for this type of obstruction is atherosclerosis, which is characterized by fatty deposition or plaque build-up in the blood vessels.

Request to Get Sample Pages at:  

                                                  https://www.pharmaproff.com/request-sample/1103

Ischemic stroke is categorized into two types which includes embolic stroke and thrombotic stroke. According to the American Stroke Association, strokes are the second leading cause of death in the world. Several risk factors associated with the ischemic stroke are high blood pressure, diabetes, atrial fibrillation, high cholesterol level, obesity, inactivity, unhealthy diet, smoking, and aging.

Make Enquiry Before Buying the Report:

                                                                https://www.pharmaproff.com/request-sample/1103

Lumosa Therapeutics Co. Ltd. is in the process of developing LT – 3001 as a small molecule with thrombolytic and anti-oxidative functions for the treatment of acute ischemic stroke. Some of the other companies having pipeline drugs for ischemic stroke includes International Stem Cell Corporation, and NoNO Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Infantile Spasm Therapeutics - Pipeline Analysis, Clinical Trials and Results

Infantile spasm, also known as West syndrome, is a rare type of seizure disorder which is characterized by sudden stiffening of the body, legs and arms, and forward bending of head. It is diagnosed by physical examination, neurological examination, electroencephalography (EEG), magnetic resonance imaging (MRI), blood tests and urine tests.

Request to Get Sample Pages at:  

                                                         https://www.pharmaproff.com/request-sample/1102

The treatment for infantile spasm includes steroid therapy with adrenocorticotropic hormone, seizure medications, ketogenic diet and epilepsy surgery. Children suffering from infantile spasm have intellectual disabilities, developmental delay and can develop autism in life.

GW Pharmaceuticals plc is in the process of developing Epidiolex, as a cannabinoid product candidate for the treatment of infantile spasm. Catalyst Pharmaceuticals Inc. and NovelMed Inc. are some other key players having pipeline drugs for infantile spasm.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                      https://www.pharmaproff.com/enquiry/1102

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hyperalgesia Therapeutics - Pipeline Analysis, Clinical Trials & Results

Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia.

Request to Get Free Sample Pages at:  https://www.pharmaproff.com/request-sample/1100

Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1100

The disease can be treated with non-opioid medications, methadone, buprenorphine, and ketamine. Company like Rottapharm Biotech Srl is in the process of developing CRB0089 as an anti-TrkA therapeutic monoclonal antibody for the treatment of hyperalgesia.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Essential Tremor Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

Essential tremor, a nerve disorder, is characterized by involuntary tremors or shaking in different parts of the body. The most common affected areas are head, arms, hands, larynx, chin and tongue.

This disease creates difficulties in daily activities such as eating, writing and dressing. Essential tremor is caused by genetic defects which results in abnormal brain activity. The disease is also linked with other movement disorders including Parkinson’s disease, migraine and headache. Essential tremor can be treated by medications, and deep brain stimulation devices.

Request to Get Free Sample Pages at:  https://www.pharmaproff.com/request-sample/1099

Neurocrine Biosciences Inc. is in the process of developing NBI-640756, an oral small molecule, for the treatment of essential tremor. Cavion Inc. is other key player involved in the development of drugs for the management of this medical condition.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1099

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Dravet Syndrome Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus.

Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due to the condition. Absence seizures, tonic-clonic seizures, atonic seizures, and myoclonic seizures are some other types of seizure associated with Dravet syndrome.

Request to Get Free Sample Pages at: 

https://www.pharmaproff.com/request-sample/1098

Zogenix Inc. is in the process of developing ZX008 as a serotonin receptor agonist for the treatment of Dravet syndrome. Ovid Therapeutics Inc. is also in the process of developing OV 935, a CH24H inhibitor, for the management of this medical condition. Insys Therapeutics Inc., and SAGE Therapeutics Inc. are some other major players having pipeline drugs for Dravet syndrome.

Make Enquiry Before Buying the Report:

https://www.pharmaproff.com/enquiry/1098

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Dementia Therapeutics - Pipeline Analysis, Clinical Trials & Results

Dementia is a group of neurological disorders which is characterized by impaired intellectual functioning. People having dementia generally lose the ability to maintain emotional control and solve the problems.

Dementia can lead to the number of cognitive and psychological changes in the body such as memory loss, difficulty in communication, confusion and disorientation, depression, anxiety, personality changes, and hallucination. In this condition, the progressive loss of neurons leads to impaired mental functioning. People with dementia are in the need of prominent supervision to prevent them from harming others or themselves.

Request to Get Free Sample Pages at:  

                                                       https://www.pharmaproff.com/request-sample/1097

Charsire Biotechnology Corp. is in the process of developing CSTC 1 (BAC) for the treatment of dementia. Stemedica Cell Technologies Inc. is also in the process of developing human mesenchymal stem cells for the treatment of dementia. Asceneuron SA, and Avanir Pharmaceuticals Inc. are some other major companies involved in development of drugs for the management of dementia.

Make Enquiry Before Buying the Report:

                                               https://www.pharmaproff.com/request-customization/1097

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Complex Regional Pain Syndrome (CRPS) Therapeutics - Pipeline Analysis

Complex regional pain syndrome (CRPS) is a type of chronic pain that affects one limb of the body (hand, leg, arm, or foot). The condition generally arises due to severe injuries or malfunctioning of central and peripheral nervous systems.

Request to Get Free Sample Pages at:  

                                                        https://www.pharmaproff.com/enquiry/1096

CRPS is categorized into two main types: CRPS-I and CRPS-II. CRPS-I is associated with unconfirmed nerve injury; whereas, CRPS-II is associated with confirmed nerve injury. CRPS can be characterized by ‘pins and needles’, or ‘burning sensation’; or it feels like someone squeezing the affected limb. People having CRPS generally experience change in skin color and temperature, and swelling in the affected area.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/crps-therapeutics-pipeline-analysis

Axsome Therapeutics Inc., and Grünenthal Group are two major companies involved in the development of drugs for the management of CRPS. The Grünenthal Group is in the process of developing T121, a bone resorption inhibitor, for the treatment of CRPS. Axsome Therapeutics Inc. is also developing AXS-02 as a bone resorption factor inhibitor for the treatment of CRPS.

Make Enquiry Before Buying the Report:

                                                         https://www.pharmaproff.com/enquiry/1096

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Cognitive Impairment Therapeutics Pipeline Analysis | Stages, Drug Class, Company Profile

Cognitive impairment is a medical condition in which people lose their cognitive capabilities such as thinking skills and memory. People having cognitive impairment are at high risk of developing dementia or Alzheimer’s disease. 

Cognitive impairment that affects memory is known as amnestic mild cognitive impairment (MCI); and the condition which affects thinking skills called nonamnestic MCI. Medical professionals diagnose cognitive impairment by asking some questions which are related to medical history, daily activities, for the assessment of the mental status of the patients. Certain blood tests and brain structure’s imaging are also used to diagnose cognitive impairment.

Request to Get Free Sample Pages at:  

                                             https://www.pharmaproff.com/request-sample/1095

AgeneBio Inc., Heptares Therapeutics Ltd., Omeros Corporation, and Asceneuron SA are some major companies involved in development of drugs for the management of cognitive impairment. For instance, AgeneBio Inc. is in the process of developing AGB101, a SV2A protein modulator, for the management of cognitive impairment.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/cognitive-impairment-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                     https://www.pharmaproff.com/enquiry/1095

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Cerebral Palsy Therapeutics - Pipeline Analysis | Clinical Trials & Results

In cerebral palsy, the term cerebral refers to brain and palsy refers to the loss or impairment of motor function. Cerebral palsy is a group of neurological disorders that appear in infancy or early childhood, and permanently affect body movement and muscle coordination.

Request to Get Free Sample Pages at:  

                                                    https://www.pharmaproff.com/request-sample/1093

It is caused by damage or abnormalities inside the developing brain that disrupt its ability to control movement and maintain posture and balance. Cerebral palsy affects the motor area of the brain’s outer layer (called the cerebral cortex), that directs muscle movement.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/cerebral-palsy-therapeutics-pipeline-analysis

In some cases, the cerebral motor cortex is not developed normally during fetal growth. In other case the damage is a result of injury to the brain either before, during, or after birth. In either case, the damage is not repairable and the disabilities that result are permanent. Children with cerebral palsy exhibit a wide variety of symptoms like lack of muscle coordination when performing voluntary movements (ataxia), stiff or tight muscles and exaggerated reflexes (spasticity), weakness in one or more arm or leg, walking on the toes, and a crouched gait. Some drug candidates of cerebral palsy pipeline include, but are not limited to, Incobotulinumtoxin A and botulinum toxin type A.

Make Enquiry Before Buying the Report:

                                                  https://www.pharmaproff.com/enquiry/1093

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Pharmacological Therapies for Asperger Syndrome

Asperger syndrome is an autism spectrum disorder characterized by impaired communication skills and repetitive thoughts or behavior. Symptoms associated with the Asperger syndrome are lack of speech recognition skills, dislike for routine changes, avoidance of eye contacts, unusual facial expressions, and delayed motor development.

Request to Get Free Sample Pages at:  

                                                     https://www.pharmaproff.com/request-sample/1092

The treatment of the disease involves social training skills, medications, and cognitive behavioral therapy. However, the actual cause of the disease is still unknown. AgeneBio Inc. is in the process of developing GABAA α5 positive allosteric modulator for the treatment of Asperger syndrome. GW Pharmaceuticals plc is in the process of developing GWP42006 as a cannabinoid receptor modulator for the treatment of this disease.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/asperger-syndrome-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                               https://www.pharmaproff.com/enquiry/1092

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More